Evaluating outcomes for patients with primary-metastatic gastrointestinal cancer

$25,241ZIAFY2022CANIH

Division Of Basic Sciences - Nci

Investigators

Linked publications, trials & patents

Paper 38245643 Paper 37947975 Paper 35817563 Paper 35668307 Paper 35661956 Paper 35527328 Paper 35524087 Paper 35451728 Paper 35412204 Paper 35388076 Paper 35258767 Paper 35229218 Paper 35061122 Paper 35022622 Paper 34994893 Paper 34897212 Paper 34783947 Paper 34671883 Paper 34643667 Paper 34471985 Paper 34216724 Paper 34132951 Paper 34117578 Paper 34117573 Paper 34117572 Paper 34032959 Paper 34012620 Paper 33999346 Paper 33987761 Paper 33987757 Paper 33978888 Paper 33933279 Paper 33932537 Paper 33836455 Paper 33819849 Paper 33786456 Paper 33397682 Paper 33345554 Paper 33239787 Paper 33206267 Paper 33057943 Paper 32705611 Paper 32703677 Paper 32618667 Paper 32510655 Paper 32437494 Paper 32422580 Paper 32282337 Paper 32189170 Paper 32175112 Paper 31996388 Paper 31944498 Paper 31925595 Paper 31898094 Paper 31749079 Paper 31734237 Paper 31570787 Paper 31447392 Paper 31326265 Paper 31243664 Paper 31102094 Paper 31044430 Paper 31011903 Paper 30895496 Paper 30877618 Paper 30511132 Paper 30463745 Paper 30143231 Paper 30141091 Paper 29725898 Paper 29339034 Paper 29334563 Paper 28767564

Abstract

As a surgical oncologist and hepatopancreatobiliary surgeon, I specialize in the treatment of pancreatic tumors and tumors of the liver and bile ductsoal and I provide patients undergoing resection of localized tumor(s) with novel adjunctive therapies to prevent recurrence of their disease at a later time. The goal of this project is to bridge clinical and translational evaluation of GI cancers, which often forms the basis of hypothesis-driven basic research. I opened a new trial this year NCT03801915 Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers.

View original record on NIH RePORTER →